FOQUEST has now been included on the Newfoundland and Labrador Prescription Drug Program (NLPDP) as of Aug 30, 2023
FOQUEST is now listed on the Newfoundland and Labrador Prescription Drug Program (NLPDP) benefit list as an Open Benefit for the treatment of persons with Attention Deficit Hyperactivity Disorder, effective Aug 30, 2023.
Learn more about the eligibility criteria for reimbursement of FOQUEST in Newfoundland and Labrador.